logo

Lyra Therapeutics, Inc. (LYRA)



Trade LYRA now with
  Date
  Headline
10/4/2021 7:09:04 AM Lyra Therapeutics Presents New Positive Phase 2 LANTERN 6-Month Follow-Up And LYR-210 Pharmacokinetic Data
9/13/2021 7:11:35 AM Lyra Therapeutics Appoints Jason Cavalier As CFO
6/30/2021 7:15:39 AM Lyra Therapeutics Announces Positive Topline Results Of Pharmacokinetic Study Of LYR-210 In Chronic Rhinosinusitis
6/2/2021 7:31:27 AM Lyra, LianBio Announce Strategic Partnership And License Deal To Develop LYR-210 In Greater China And Asian Markets
2/17/2021 8:25:21 AM Lyra Therapeutics Names Robert Kern Chief Medical Officer
1/22/2021 8:09:53 AM Lyra To Initiate Phase 2 Trial For LYR-220 And To Explore Further Opportunities
12/7/2020 8:09:41 AM Lyra Therapeutics Announces Positive Topline Results From LANTERN Phase 2 Study Of LYR-210 For Chronic Rhinosinusitis
8/4/2020 8:09:36 AM Lyra Therapeutics Announces Pamela Nelson As SVP Of Regulatory Affairs
7/7/2020 8:36:47 AM Lyra Therapeutics Appoints Robert Richard SVP Of Research And Development
5/5/2020 10:02:31 AM Lyra Therapeutics Announces Closing Of IPO